{"description":"Adverse events were monitored for each cycle during therapy and during follow-up and graded using the National Cancer Institute Common Toxicity Criteria (CTC) version 3.0. Frequencies for toxicity and adverse events were recorded.\n\nAlthough adverse events were monitored, however, not all adverse events are being reported. The PI and the study team have left the institution. Sincere efforts were made to obtain the data, however, the adverse events data is not available.","eventGroups":[{"deathsNumAffected":0,"deathsNumAtRisk":27,"description":"Adjuvant Radiation Therapy \"Sandwiched\" between Ifosfamide in Patients with Mixed Mesodermal Tumors\n\nRadiation Therapy : Ifosfamide 1.2gm/m2/day for 5 days. Mesna 400mg/IVSS bolus at each ifosfamide dosing followed by 1200mg IV divided in 3L/day x 5 days. Repeat q21 days x 3 cycles. After 3 cycles, RT. After RT, Ifosfamide 1.0gm/m2/day for 5 days. Mesna 333mg/IVSS bolus at each ifosfamide dosing followed by 1000mg IV divided in 3L/day x 5 days. Repeat q21 days x 3 cycles.\n\nIfosfamide : Ifosfamide 1.2gm/m2/day for 5 days. Mesna 400mg/IVSS bolus at each ifosfamide dosing followed by 1200mg IV divided in 3L/day x 5 days. Repeat q21 days x 3 cycles. After 3 cycles, RT. After RT, Ifosfamide 1.0gm/m2/day for 5 days. Mesna 333mg/IVSS bolus at each ifosfamide dosing followed by 1000mg IV divided in 3L/day x 5 days. Repeat q21 days x 3 cycles.","id":"EG000","otherNumAffected":0,"otherNumAtRisk":27,"seriousNumAffected":13,"seriousNumAtRisk":27,"title":"Chemotherapy and Radiation Therapy"}],"frequencyThreshold":"0","seriousEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"low count of white blood cells.","organSystem":"Blood and lymphatic system disorders","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":27}],"term":"Neutropenia"}],"timeFrame":"Participants were followed up to 2 years."}